federal judge in Florida sentenced Charles and Patrick Boyd to a cumulative 38 years in prison. The brothers owned Safe Chain Solutions, a Cambridge, Maryland-based drug distributor at the center of a diversion ring that endangered the health of American patients by selling U.S. pharmacies over 85,00 counterfeit bottles of secondhand HIV medicine worth more than $250 million.
Sanjay Kumar got 43 months for selling counterfeit Keytruda. PSM wrote federal agencies about a Super Bowl ad promoting diagnostic tests and compounded medicines with false claims.
On February 26, 2026, PSM was glad to see the Indiana legislature pass SB 282, a bill that strengthens compounding and medical spa regulation to keep Indiana patients safer.
As Europol seized a huge amounts of counterfeit pharmaceuticals abroad, a Kentucky legislator proposed a bill to regulate med spas after a constituent was seriously injured and adverse events related to weight loss drugs see surges across the US.
Washington State investigators found serious violations at a Mochi Health-affiliated compounding pharmacy producing GLP-1s, and a med spa bill in Indiana hears public testimony about a med spa bill.
Industry experts told us that these two companies are on the FDA’s Green List, despite problematic inspections in late 2024 and early 2025. Learn what the inspectors found.
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
A Pennsylvania compounding pharmacy received another FDA warning letter following a series of enforcement actions, including a $1 million state fine in October.
The last two months of 2025 saw thousands of shipments of drugs popularized by social media imported into the U.S., as well as Xarelto and antibiotics. The shipments carried a wide range of product codes; some appropriate, and others far less so.
On February 17, PSM submitted written and oral testimony in opposition to Colorado HB26-1056, which would permit self-insured employers to use alternative funding programs to import foreign medicines from outside the U.S. drug supply chain.